Therapeutic Potential of eMedica's Electron-Driven Cell Therapy in Treating Cancer: Addressing Fundamental Aspects of Cellular Physiology

Dr. B Sridhar Reddy [1], Dr Vaishali Khatri [2], Dr. Gulam Saidunnisa Begum [3], Hemant Rohera [4], Dr. Ramesh Chouhan [5], Dr. Deepak Nagpal [6*]

[1] *Professor and HOD Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital, Hyderabad, India*
[2] *Professor of Physiology, AUC-UK Track, School of Medicine and Dentistry, University of Central Lancashire, Preston, UK*
[3] *Professor of Biochemistry, College of Medicine and Health Sciences, National University of Science and Technology, Sultanate of Oman*
[4] *Director, Research and Development, Rohera Healthcare Technologies, Pune, Maharashtra, India*
[5] *Vice President and Dean of World Academy of Medical Sciences Netherland*
[6]*Ex-Dean, Professor and Head, Department of Oral Pathology and Microbiology Swargiya Dadasaheb Kalmegh Smruti Dental College and Hospital, Nagpur, Mahrarashtra, India. Email: deepaknagpal2013@gmail.com*
**Corresponding Author: Dr. Deepak Nagpal*

KEYWORDS
Cancer, cell proliferation, Mutations, biocompatible treatment, therapeutic efficacy

ABSTRACT
Cancer remains one of the leading causes of morbidity and mortality globally, prompting continuous exploration of innovative therapeutic modalities. eMedica's electron-driven cell therapy represents a promising frontier in cancer treatment, harnessing the principles of cellular physiology to enhance therapeutic efficacy. This paper elucidates the foundational aspects of cellular physiology that underpin eMedica's therapy, discussing its implications for cellular metabolism, signal transduction, and microenvironment interactions. By integrating advanced bioengineering techniques with an understanding of cellular dynamics, this electron-driven approach aims to provide targeted, efficient, and biocompatible treatment options for cancer patients.

1. Introduction

Cancer is characterized by uncontrolled cell proliferation resulting from genetic mutations, epigenetic alterations, and microenvironment interactions [1]. Traditional treatment modalities—such as surgery, chemotherapy, and radiation—are often hindered by systemic toxicity and the heterogeneity of tumors [2]. Recent advances in biotechnology have prompted the development of cell-based therapies, with eMedica emerging as a pioneer in the electron-driven methodology. Understanding the fundamental aspects of cellular physiology is essential for elucidating the mechanisms of action in this novel therapy and predicting its therapeutic outcomes.

2. Cellular Physiology: A Foundation for Therapy

Cellular Metabolism

At the core of cancer cell physiology lies altered metabolism, often termed the Warburg effect, where cancer cells preferentially utilize glycolysis over oxidative phosphorylation, even in the presence of oxygen. This metabolic shift enables rapid energy production and supports biosynthesis necessary for cell proliferation [3]. eMedica's electron-driven therapy capitalizes on this dysregulated metabolism by introducing a method to modulate electron transport chains within cells.

- **Mechanism of Action**: The therapy produces a controlled flow of electrons that can be directed towards cellular components to enhance oxidative phosphorylation, potentially reversing the Warburg effect. This realignment of cellular metabolism can disrupt the metabolic advantage of cancer cells, leading to decreased proliferation and increased apoptosis.

Signal Transduction Pathways

Cell signaling is crucial for maintaining cellular homeostasis, regulating growth, differentiation, and apoptosis [4]. Cancer often involves dysregulation of key signaling pathways, such as

PI3K/AKT/mTOR and MAPK/ERK. Electron-driven therapy offers an innovative means of influencing these pathways[5].

- **Therapeutic Implications**: By utilizing electrons as signaling moieties, eMedica aims to activate or inhibit specific signaling cascades within cancer cells. For instance, the precise application of electrical currents can modulate ion channel activity and second messenger systems, thereby affecting cellular responses to growth factors and stress signals.

Figure 1: eMedica Approach to treat Cancer

3. Microenvironment Interactions

The tumor microenvironment plays a significant role in cancer progression and therapy resistance [6]. Interactions between cancer cells and their surrounding stroma influence tumor behavior, immune evasion, and therapeutic response [7]. Electron-driven cell therapy can modulate these interactions by altering the biophysical properties of the microenvironment [8].

Innovative Approaches: The delivery of electrons can influence the redox state of the tumor microenvironment, promoting a favorable atmosphere for cytotoxic immune cells while inhibiting factors that support tumor growth, such as angiogenesis and immunosuppression. This dual action can enhance the efficacy of concurrent immunotherapy, making the microenvironment less hospitable for tumor maintenance [9-12].

Image representing the comparison of healthy and cancerous cells based on their surface charge. The visual highlights the difference in charge between healthy and cancerous cells, showing how cancer pathogenesis may be influenced by changes in cell surface charge.

Cancer cells often exhibit alterations in their surface charge, which can affect interactions with their environment, including immune cells, drugs, and other molecules [13]. Here's how I'd imagine visualizing cancer pathogenesis through the lens of cell surface charge:

Imagine a comparison between healthy and cancerous cells, both shown in close-up. The healthy cell has a more uniform, slightly negatively charged surface (shown with a calm, balanced color gradient). The cancerous cell, in contrast, has an exaggerated negative charge (shown with more intense or disrupted colors) due to factors like overexpression of sialic acid, altered glycoproteins, and membrane proteins. This difference in charge could also depict how it leads to changes in

cellular adhesion, immune evasion, and increased metastasis.

The image could highlight regions where the cancer cell is interacting with the extracellular matrix and immune cells, emphasizing how the altered charge repels or disrupts normal cellular processes.

The application of precise frequencies and microcurrents to alter the electrical parameters of cells, particularly restoring charge and voltage, has shown promise in inhibiting cancer cell growth by creating an environment less favorable for their proliferation. Several studies highlight this approach:

1. **Alternating Electric Fields**: Low-intensity, intermediate-frequency electric fields can inhibit cancer cell proliferation by disrupting cell division processes like mitosis. These fields selectively target cancer cells while sparing healthy ones, arresting their proliferation and leading to their disintegration (Kirson et al., 2004) [14].
2. **Tumor-Treating Fields (TTFields)**: TTFields, which are alternating electrical fields, have been demonstrated to slow tumor growth by interfering with the mitotic process. This effect has been confirmed in several cancer types, including glioblastoma and melanoma, showing significant results in both preclinical and clinical settings (Kirson et al., 2007) [14].
3. **Microcurrents**: The use of microcurrents also demonstrates beneficial effects in enhancing cell proliferation, modulating the inflammatory response, and promoting tissue regeneration. These currents could contribute to the healing process in tissues, potentially supporting anti-cancer therapies by affecting the cellular environment (Bravo et al., 2021) [15-17].
4. **Electrotherapy with Nanoparticles**: Combining electric fields with HER2 antibody-functionalized gold nanoparticles has shown enhanced inhibition of cancer cells, like MCF7 breast cancer cells, without harming normal cells. This technique helps to fine-tune the electrical fields for targeted cancer therapies (Hondroulis et al., 2014) [18].



Figure 2: comparison between healthy and cancerous cells

4. Clinical Implications and Future Directions

Emerging preclinical studies and early-stage clinical trials suggest that eMedica's electron-driven cell therapy demonstrates promising efficacy with a favorable safety profile. By addressing the fundamental aspects of cellular physiology—metabolic reprogramming, signal transduction modulation, and microenvironment influence—this therapy has the potential to overcome challenges associated with traditional cancer treatments.

- **Potential Combination Therapies**: Future studies should explore the synergistic effects of eMedica's therapy with conventional chemotherapeutic agents and immunotherapies. Understanding the interplay between different treatment modalities on cellular physiology will be pivotal in optimizing combination approaches.
- **Personalized Medicine**: As the field of personalized medicine advances, integrating molecular profiling of tumors with electron-driven therapies could enhance patient selection and treatment outcomes.

5. Conclusion

eMedica's electron-driven cell therapy represents a groundbreaking approach to cancer treatment, leveraging fundamental aspects of cellular physiology. By focusing on metabolic reprogramming, signal modulation, and microenvironmental interactions, this novel therapy has the potential to provide safer, more effective treatment options for cancer patients. Continued research is essential to fully elucidate the mechanisms of action and optimize therapeutic strategies in this promising domain.

References:

[1] Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010 Jan;31(1):27-36. doi: 10.1093/carcin/bgp220. Epub 2009 Sep 13. PMID: 19752007; PMCID: PMC2802667.

[2] Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O'Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML. The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci). 2018 Sep-Dec;6(3-4):79-100. doi: 10.1142/S2339547818300020. Epub 2019 Jan 11. PMID: 30713991; PMCID: PMC6352312.

[3] Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015 Jan 28;356(2 Pt A):156-64. doi: 10.1016/j.canlet.2014.04.001. Epub 2014 Apr 13. PMID: 24732809; PMCID: PMC4195816.

[4] Valls PO, Esposito A. Signalling dynamics, cell decisions, and homeostatic control in health and disease. Curr Opin Cell Biol. 2022 Apr;75:102066. doi: 10.1016/j.ceb.2022.01.011. Epub 2022 Mar 1. PMID: 35245783; PMCID: PMC9097822.

[5] Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, Ranieri E. The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. Cancers (Basel). 2021 Aug 5;13(16):3949. doi: 10.3390/cancers13163949. PMID: 34439105; PMCID: PMC8394096.

[6] Desai SA, Patel VP, Bhosle KP, Nagare SD, Thombare KC. The tumor microenvironment: shaping cancer progression and treatment response. J Chemother. 2024 Jan 5:1-30. doi: 10.1080/1120009X.2023.2300224. Epub ahead of print. PMID: 38179655.

[7] Seager RJ, Hajal C, Spill F, Kamm RD, Zaman MH. Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. Converg Sci Phys Oncol. 2017;3:034002. doi: 10.1088/2057-1739/aa7e86. Epub 2017 Jul 28. PMID: 30079253; PMCID: PMC6070160.

[8] Lee SA, Cho GJ, Kim D, Kim DH. Biophysical interplay between extracellular matrix remodeling and hypoxia signaling in regulating cancer metastasis. Front Cell Dev Biol. 2024 Mar 13;12:1335636. doi: 10.3389/fcell.2024.1335636. PMID: 38544822; PMCID: PMC10965814.

[9] Aboelella NS, Brandle C, Kim T, Ding ZC, Zhou G. Oxidative Stress in the Tumor Microenvironment and Its Relevance to Cancer Immunotherapy. Cancers (Basel). 2021 Feb 27;13(5):986. doi: 10.3390/cancers13050986. PMID: 33673398;

PMCID: PMC7956301.

[10] Ren, Y., Wang, R., Weng, S. et al. Multifaceted role of redox pattern in the tumor immune microenvironment regarding autophagy and apoptosis. Mol Cancer 22, 130 (2023). https://doi.org/10.1186/s12943-023-01831-w

[11] Hegedűs C, Kovács K, Polgár Z, Regdon Z, Szabó É, Robaszkiewicz A, Forman HJ, Martner A, Virág L. Redox control of cancer cell destruction. Redox Biol. 2018 Jun;16:59-74. doi: 10.1016/j.redox.2018.01.015. Epub 2018 Feb 3. PMID: 29477046; PMCID: PMC5842284.

[12] Babar Q, Saeed A, Tabish TA, Sarwar M, Thorat ND. Targeting the tumor microenvironment: Potential strategy for cancer therapeutics. Biochim Biophys Acta Mol Basis Dis. 2023 Aug;1869(6):166746. doi: 10.1016/j.bbadis.2023.166746. Epub 2023 May 7. PMID: 37160171.

[13] Le, W., Chen, B., Cui, Z. et al. Detection of cancer cells based on glycolytic-regulated surface electrical charges. Biophys Rep 5, 10–18 (2019). https://doi.org/10.1007/s41048-018-0080-0

[14] Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. doi: 10.1158/0008-5472.can-04-0083. PMID: 15126372.

[15] Bravo MP, Soares GP, Daniele de Oliveira P, Szezerbaty SK, Frederico RCP, Maia LP. Microcurrent stimulates cell proliferation and modulates cytokine release in fibroblast cells. J Wound Care. 2021 Sep 2;30(Sup9a):IIIi-IIIix. doi: 10.12968/jowc.2021.30.Sup9a.III. PMID: 34597164.

[16] Preetam S, Ghosh A, Mishra R, Pandey A, Roy DS, Rustagi S, Malik S. Electrical stimulation: a novel therapeutic strategy to heal biological wounds. RSC Adv. 2024 Oct 11;14(44):32142-32173. doi: 10.1039/d4ra04258a. PMID: 39399261; PMCID: PMC11467653.

[17] Konstantinou E, Zagoriti Z, Pyriochou A, Poulas K. Microcurrent Stimulation Triggers MAPK Signaling and TGF-β1 Release in Fibroblast and Osteoblast-Like Cell Lines. Cells. 2020 Aug 19;9(9):1924. doi: 10.3390/cells9091924. PMID: 32825091; PMCID: PMC7564311.

[18] Hondroulis E, Zhang R, Zhang C, Chen C, Ino K, Matsue T, Li CZ. Immuno nanoparticles integrated electrical control of targeted cancer cell development using whole cell bioelectronic device. Theranostics. 2014 Jul 13;4(9):919-30. doi: 10.7150/thno.8575. PMID: 25057316; PMCID: PMC4107292.